{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:48:22Z","timestamp":1782776902068,"version":"3.54.5"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"DOI":"10.1186\/s44158-026-00396-6","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T03:06:08Z","timestamp":1778123168000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Landiolol in perioperative and critical care: evidence, patient selection, and practical titration for targeted heart rate control: a narrative review"],"prefix":"10.1186","volume":"6","author":[{"given":"Cesare","family":"Biuzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Carinci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Sorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Bidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Albizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marianello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Franchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Paternoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio Silvio","family":"Taccone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"Scolletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"9","key":"396_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(20)30037-0","volume":"8","author":"Y Kakihana","year":"2020","unstructured":"Kakihana Y, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H et al (2020) Efficacy and safety of landiolol, an ultra-short-acting \u03b21-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial. Lancet Respir Med 8(9):863\u2013872. https:\/\/doi.org\/10.1016\/S2213-2600(20)30037-0","journal-title":"Lancet Respir Med"},{"key":"396_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100571","volume":"28","author":"N Matsuda","year":"2020","unstructured":"Matsuda N, Nishida O, Taniguchi T, Okajima M, Morimatsu H, Ogura H et al (2020) Impact of patient characteristics on the efficacy and safety of landiolol in patients with sepsis-related tachyarrhythmia: subanalysis of the J-Land 3S randomised controlled study. EClinicalMedicine 28:100571. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100571","journal-title":"EClinicalMedicine"},{"issue":"10","key":"396_CR3","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00134-024-07587-1","volume":"50","author":"S Rehberg","year":"2024","unstructured":"Rehberg S, Frank S, \u010cern\u00fd V, Cihl\u00e1\u0159 R, Borgstedt R, Biancofiore G et al (2024) Landiolol for heart rate control in patients with septic shock and persistent tachycardia. A multicenter randomized clinical trial (Landi-SEP). Intensive Care Med 50(10):1622\u20131634. https:\/\/doi.org\/10.1007\/s00134-024-07587-1","journal-title":"Intensive Care Med"},{"issue":"8","key":"396_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1253\/circrep.CR-20-0017","volume":"2","author":"T Shiga","year":"2020","unstructured":"Shiga T, Ikeda T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R et al (2020) Efficacy and safety of landiolol in patients with ventricular tachyarrhythmias with or without renal impairment \u2015 subanalysis of the J-Land II Study. Circ Rep 2(8):440\u2013445. https:\/\/doi.org\/10.1253\/circrep.CR-20-0017","journal-title":"Circ Rep"},{"key":"396_CR5","doi-asserted-by":"publisher","unstructured":"Ratajska P, Wilawer M, Burchardt P. Heart failure, atrial fibrillation, and landiolol \u2013 a new, ultra-short-acting beta-blocker. Review of the literature. 4th ed. PL: Wydawnictwo Akademia Medycyny; 2023. 233 (Farmacja Wsp\u00f3\u0142czesna). https:\/\/doi.org\/10.53139\/FW.20231633","DOI":"10.53139\/FW.20231633"},{"key":"396_CR6","unstructured":"Agenzia Italiana del Farmaco. Landiololo. AIFA; [cited 2025 Feb 5]. Available from: https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/organizzazione\/4340\/farmaci\/44274\/stampati\/FI"},{"issue":"1","key":"396_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s44158-023-00126-2","volume":"3","author":"F Guarracino","year":"2023","unstructured":"Guarracino F, Cortegiani A, Antonelli M, Behr A, Biancofiore G, Del Gaudio A et al (2023) The role of beta-blocker drugs in critically ill patients: a SIAARTI expert consensus statement. J Anesth Analg Crit Care 3(1):41. https:\/\/doi.org\/10.1186\/s44158-023-00126-2","journal-title":"J Anesth Analg Crit Care"},{"key":"396_CR8","doi-asserted-by":"publisher","unstructured":"Ghallab M, Ahmed MS, Ostrow TH, Rasool MH, Alagha Z, Miller D et al (2024) Landiolol for treating arrhythmias: a state-of-the-art review. Cardiol Rev. https:\/\/doi.org\/10.1097\/CRD.0000000000000687","DOI":"10.1097\/CRD.0000000000000687"},{"issue":"5","key":"396_CR9","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1002\/ehf2.12879","volume":"7","author":"T Imamura","year":"2020","unstructured":"Imamura T, Kinugawa K (2020) Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation. ESC Heart Fail 7(5):2208\u20132213. https:\/\/doi.org\/10.1002\/ehf2.12879","journal-title":"ESC Heart Fail"},{"issue":"suppl_A","key":"396_CR10","doi-asserted-by":"publisher","first-page":"A19","DOI":"10.1093\/eurheartj\/sux035","volume":"20","author":"S Von Haehling","year":"2018","unstructured":"Von Haehling S, B\u011blohl\u00e1vek J, Er F, Gassanov N, Guarracino F, Bouvet O (2018) Landiolol for rate control management of atrial fibrillation in patients with cardiac dysfunction. Eur Heart J Suppl 20(suppl_A):A19-24. https:\/\/doi.org\/10.1093\/eurheartj\/sux035","journal-title":"Eur Heart J Suppl"},{"issue":"suppl_A","key":"396_CR11","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1093\/eurheartj\/sux038","volume":"20","author":"JL Fellahi","year":"2018","unstructured":"Fellahi JL, Heringlake M, Knotzer J, Fornier W, Cazenave L, Guarracino F (2018) Landiolol for managing atrial fibrillation in post-cardiac surgery. Eur Heart J Suppl 20(suppl_A):A4-9. https:\/\/doi.org\/10.1093\/eurheartj\/sux038","journal-title":"Eur Heart J Suppl"},{"key":"396_CR12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88004","author":"S Paneer Selvam","year":"2025","unstructured":"Paneer Selvam S, Gamarra-Valverde NN, Tripoli A, Samaniego MA, Giorgi J (2025Jul 15) Efficacy and safety of landiolol in the treatment of tachycardia in patients with sepsis and septic shock: a systematic review and meta-analysis. Cureus. https:\/\/doi.org\/10.7759\/cureus.88004","journal-title":"Cureus"},{"issue":"suppl_A","key":"396_CR13","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1093\/eurheartj\/sux037","volume":"20","author":"H Domanovits","year":"2018","unstructured":"Domanovits H, Wolzt M, Stix G (2018) Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting. Eur Heart J Suppl 20(suppl_A):A1-3. https:\/\/doi.org\/10.1093\/eurheartj\/sux037","journal-title":"Eur Heart J Suppl"},{"issue":"9","key":"396_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40265-013-0077-4","volume":"73","author":"GL Plosker","year":"2013","unstructured":"Plosker GL (2013) Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs 73(9):959\u2013977. https:\/\/doi.org\/10.1007\/s40265-013-0077-4","journal-title":"Drugs"},{"key":"396_CR15","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2024.18","volume":"11","author":"G Koukoulitsios","year":"2025","unstructured":"Koukoulitsios G, Tsikritsaki K, Magklaras G, Koutivas AM, Kalogeromitros A, Papaioannou V (2025) Comparison of landiolol and esmolol on haemodynamic responses during weaning of intensive care unit patients with reduced ejection fraction after vascular surgery. Card Fail Rev 11:e13. https:\/\/doi.org\/10.15420\/cfr.2024.18","journal-title":"Card Fail Rev"},{"issue":"1","key":"396_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13613-024-01418-8","volume":"15","author":"X Si","year":"2025","unstructured":"Si X, Yuan H, Shi R, Song W, Guo J, Jiang J et al (2025) Comparison of the efficacy and safety of landiolol and esmolol in critically ill patients: a propensity score-matched study. Ann Intensive Care 15(1):5. https:\/\/doi.org\/10.1186\/s13613-024-01418-8","journal-title":"Ann Intensive Care"},{"issue":"2","key":"396_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/CCM.0000000000006966","volume":"54","author":"Z Tang","year":"2026","unstructured":"Tang Z, Sun Q, Xu J, Yang Y, Peng F (2026) Comparison of esmolol versus landiolol on mortality in adult patients with sepsis: a systematic review and network meta-analysis. Crit Care Med 54(2):324\u201334. https:\/\/doi.org\/10.1097\/CCM.0000000000006966","journal-title":"Crit Care Med"},{"issue":"36","key":"396_CR18","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM et al (2024) 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 45(36):3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"issue":"10","key":"396_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13102951","volume":"13","author":"B Levy","year":"2024","unstructured":"Levy B, Slama M, Lakbar I, Maizel J, Kato H, Leone M et al (2024) Landiolol for treatment of new-onset atrial fibrillation in critical care: a systematic review. JCM 13(10):2951. https:\/\/doi.org\/10.3390\/jcm13102951","journal-title":"JCM"},{"issue":"4","key":"396_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/j.1365-2710.2011.01315.x","volume":"37","author":"T Nakano","year":"2012","unstructured":"Nakano T, Shimizu K, Kawashima O, Kamiyoshihara M, Nagashima T, Ibe T et al (2012) Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection: effect of landiolol for post-operative tachycardia. J Clin Pharm Ther 37(4):431\u20135. https:\/\/doi.org\/10.1111\/j.1365-2710.2011.01315.x","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"396_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ph16020134","volume":"16","author":"S Schnaubelt","year":"2023","unstructured":"Schnaubelt S, Eibensteiner F, Oppenauer J, Tihanyi D, Neymayer M, Brock R et al (2023) Hemodynamic and rhythmologic effects of push-dose landiolol in critical care\u2014a retrospective cross-sectional study. Pharmaceuticals 16(2):134. https:\/\/doi.org\/10.3390\/ph16020134","journal-title":"Pharmaceuticals"},{"issue":"6","key":"396_CR22","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s00392-023-02295-0","volume":"113","author":"M Perrett","year":"2024","unstructured":"Perrett M, Gohil N, Tica O, Bunting KV, Kotecha D (2024) Efficacy and safety of intravenous beta-blockers in acute atrial fibrillation and flutter is dependent on beta-1 selectivity: a systematic review and meta-analysis of randomised trials. Clin Res Cardiol 113(6):831\u201341. https:\/\/doi.org\/10.1007\/s00392-023-02295-0","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"396_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13061683","volume":"13","author":"A Nasoufidou","year":"2024","unstructured":"Nasoufidou A, Papazoglou AS, Stachteas P, Karagiannidis E, Samaras A, Alexiou S et al (2024) Intravenous landiolol for rate control in supraventricular tachyarrhythmias in patients with left ventricular dysfunction: a systematic review and meta-analysis. JCM 13(6):1683. https:\/\/doi.org\/10.3390\/jcm13061683","journal-title":"JCM"},{"key":"396_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2020.08.514","volume":"23","author":"E Walter","year":"2020","unstructured":"Walter E, Kamali H, Siller-Matula J (2020) PCV23 cost-effectiveness of landiolol, an ultra-short-acting beta-blocker, for treatment of sepsis related tachyarrhythmia in Germany. Value Health 23:S490. https:\/\/doi.org\/10.1016\/j.jval.2020.08.514","journal-title":"Value Health"},{"issue":"Supplement_D","key":"396_CR25","doi-asserted-by":"publisher","first-page":"D22","DOI":"10.1093\/eurheartjsupp\/suac024","volume":"24","author":"S Bezati","year":"2022","unstructured":"Bezati S, Velliou M, Polyzogopoulou E, Boultadakis A, Parissis J (2022) The role of landiolol in the management of atrial tachyarrhythmias in patients with acute heart failure and cardiogenic shock: case reports and review of literature. Eur Heart J Suppl 24(Supplement_D):D22-33. https:\/\/doi.org\/10.1093\/eurheartjsupp\/suac024","journal-title":"Eur Heart J Suppl"},{"issue":"6","key":"396_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16060839","volume":"16","author":"F Eibensteiner","year":"2024","unstructured":"Eibensteiner F, Mosor E, Tihanyi D, Anders S, Kornfehl A, Neymayer M et al (2024) The impact of chronic oral beta-blocker intake on intravenous bolus landiolol response in hospitalized intensive care patients with sudden-onset supraventricular tachycardia\u2014a post hoc analysis of a cross-sectional trial. Pharmaceutics 16(6):839. https:\/\/doi.org\/10.3390\/pharmaceutics16060839","journal-title":"Pharmaceutics"},{"issue":"8","key":"396_CR27","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1007\/s00246-021-02653-7","volume":"42","author":"A Ashida","year":"2021","unstructured":"Ashida A, Ozaki N, Kishi K, Odanaka Y, Nemoto S, Konishi H (2021) Safety and efficacy of landiolol hydrochloride in children with tachyarrhythmia of various etiologies. Pediatr Cardiol 42(8):1700\u20135. https:\/\/doi.org\/10.1007\/s00246-021-02653-7","journal-title":"Pediatr Cardiol"},{"issue":"1","key":"396_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1253\/circj.CJ-21-0967","volume":"87","author":"K Sagawa","year":"2022","unstructured":"Sagawa K, Suzuki T, Takei K, Miura M, Ueda H, Horigome H et al (2022) Control of heart rate in infant and child tachyarrhythmia with reduced cardiac function using landiolol (HEARTFUL) \u2015 results of a prospective, multicenter, uncontrolled clinical study. Circ J 87(1):130\u20138. https:\/\/doi.org\/10.1253\/circj.CJ-21-0967","journal-title":"Circ J"},{"issue":"2","key":"396_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euaf025","volume":"27","author":"I Michel-Behnke","year":"2025","unstructured":"Michel-Behnke I, M\u00fcller M, Stiller B, Kriebel T, Kanaan M, K\u00f6rnyei L et al (2025) Landiolol is effective and safe in paediatric supraventricular tachycardia: evidence from a European prospective multicentre open-label phase III study (LANDI-PED). Europace 27(2):euaf025. https:\/\/doi.org\/10.1093\/europace\/euaf025","journal-title":"Europace"},{"issue":"2","key":"396_CR30","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00246-025-03824-6","volume":"47","author":"M M\u00fcller","year":"2026","unstructured":"M\u00fcller M, Puschmann LA, Zajonz T, Unger M, Ackerl J, Shatilova O (2026) Heart rate control with landiolol hydrochloride in infants and neonates during cardiac surgery. Pediatr Cardiol 47(2):709\u2013717. https:\/\/doi.org\/10.1007\/s00246-025-03824-6","journal-title":"Pediatr Cardiol"},{"issue":"9","key":"396_CR31","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1017\/S1047951125109268","volume":"35","author":"L Sandoval","year":"2025","unstructured":"Sandoval L, Arenz C, Hamann M, Chlench S (2025) An exploratory study of landiolol plus amiodarone versus amiodarone monotherapy in paediatric junctional ectopic tachycardia after surgery. Cardiol Young 35(9):1906\u201312. https:\/\/doi.org\/10.1017\/S1047951125109268","journal-title":"Cardiol Young"},{"issue":"6","key":"396_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.bja.2020.05.058","volume":"125","author":"A Morelli","year":"2020","unstructured":"Morelli A, Romano SM, Sanfilippo F, Santonocito C, Frati G, Chiostri M et al (2020) Systolic-dicrotic notch pressure difference can identify tachycardic patients with septic shock at risk of cardiovascular decompensation following pharmacological heart rate reduction. Br J Anaesth 125(6):1018\u201324. https:\/\/doi.org\/10.1016\/j.bja.2020.05.058","journal-title":"Br J Anaesth"},{"issue":"1","key":"396_CR33","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jointm.2024.07.002","volume":"5","author":"D De Backer","year":"2025","unstructured":"De Backer D, Chen D (2025) The pros and cons of beta-blockers in sepsis: where do we stand in 2024? J Intensive Med 5(1):32\u201334. https:\/\/doi.org\/10.1016\/j.jointm.2024.07.002","journal-title":"J Intensive Med"},{"issue":"5","key":"396_CR34","doi-asserted-by":"publisher","first-page":"e1125","DOI":"10.1097\/CCM.0000000000006604","volume":"53","author":"C McChesney","year":"2025","unstructured":"McChesney C, Orozco N, Fiorini K, Wong MYS, Slessarev M, Prager R et al (2025) Impact of short-acting beta-blockers on the outcomes of patients with septic shock: a systematic review and meta-analysis. Crit Care Med 53(5):e1125-39. https:\/\/doi.org\/10.1097\/CCM.0000000000006604","journal-title":"Crit Care Med"},{"issue":"17","key":"396_CR35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20134","volume":"330","author":"T Whitehouse","year":"2023","unstructured":"Whitehouse T, Hossain A, Perkins GD, Gordon AC, Bion J, Young D et al (2023) Landiolol and organ failure in patients with septic shock: The STRESS-L randomized clinical trial. JAMA 330(17):1641. https:\/\/doi.org\/10.1001\/jama.2023.20134","journal-title":"JAMA"},{"issue":"1","key":"396_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.chest.2024.08.020","volume":"167","author":"R Sato","year":"2025","unstructured":"Sato R, Messina S, Hasegawa D, Santonocito C, Scimonello G, Sanfilippo G et al (2025) Mortality in patients with sepsis treated with esmolol or landiolol. Chest 167(1):121\u201338. https:\/\/doi.org\/10.1016\/j.chest.2024.08.020","journal-title":"Chest"},{"key":"396_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000007075","author":"HC Prescott","year":"2026","unstructured":"Prescott HC, Antonelli M, Alhazzani W, M\u00f8ller MH, Alshamsi F, Azevedo LCP et al (2026Mar 23) Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026. Crit Care Med. https:\/\/doi.org\/10.1097\/CCM.0000000000007075","journal-title":"Crit Care Med"},{"issue":"1","key":"396_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ams2.70037","volume":"12","author":"N Shime","year":"2025","unstructured":"Shime N, Nakada T, Yatabe T, Yamakawa K, Aoki Y, Inoue S et al (2025) The Japanese clinical practice guidelines for management of sepsis and septic shock 2024. Acute Med Surg 12(1):e70037. https:\/\/doi.org\/10.1002\/ams2.70037","journal-title":"Acute Med Surg"},{"issue":"5","key":"396_CR39","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1177\/0310057X211009913","volume":"49","author":"PK Datta","year":"2021","unstructured":"Datta PK, Rewari V, Ramachandran R, Singh PM, Ray BR, Aravindan A et al (2021) Effectiveness of enteral ivabradine for heart rate control in septic shock: A randomised controlled trial. Anaesth Intensive Care 49(5):366\u201378. https:\/\/doi.org\/10.1177\/0310057X211009913","journal-title":"Anaesth Intensive Care"},{"issue":"1","key":"396_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12871-025-03121-y","volume":"25","author":"LA Calabr\u00f2","year":"2025","unstructured":"Calabr\u00f2 LA, Pasetto M, Scolletta S, Annoni F, Demailly Z, Halenarova K et al (2025) Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients. BMC Anesthesiol 25(1):276. https:\/\/doi.org\/10.1186\/s12871-025-03121-y. (PubMed PMID: 40448257; PubMed Central PMCID: PMC12125779.)","journal-title":"BMC Anesthesiol"},{"issue":"8","key":"396_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082338","volume":"13","author":"M Pasetto","year":"2024","unstructured":"Pasetto M, Calabr\u00f2 LA, Annoni F, Scolletta S, Labb\u00e9 V, Donadello K et al (2024) Ivabradine in septic shock: A narrative review. J Clin Med 13(8):2338. https:\/\/doi.org\/10.3390\/jcm13082338","journal-title":"J Clin Med"},{"issue":"3","key":"396_CR42","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1378\/chest.11-2604","volume":"142","author":"AC Gordon","year":"2012","unstructured":"Gordon AC, Wang N, Walley KR, Ashby D, Russell JA (2012) The cardiopulmonary effects of vasopressin compared with norepinephrine in septic shock. Chest 142(3):593\u2013605. https:\/\/doi.org\/10.1378\/chest.11-2604","journal-title":"Chest"},{"issue":"1","key":"396_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-016-1488-x","volume":"20","author":"A Rudiger","year":"2016","unstructured":"Rudiger A, Singer M (2016) Decatecholaminisation during sepsis. Crit Care 20(1):309. https:\/\/doi.org\/10.1186\/s13054-016-1488-x","journal-title":"Crit Care"},{"key":"396_CR44","doi-asserted-by":"publisher","unstructured":"Del Gaudio A, Caiazza A, Bortone L, Tomasso S, Bozzari I, Vincenzi L, et al. Decatecholaminization of septic shock patients in intensive care unit: an economic assessment in the Italian setting. FE. 2024;25(1). https:\/\/doi.org\/10.7175\/fe.v25i1.1562","DOI":"10.7175\/fe.v25i1.1562"},{"issue":"3","key":"396_CR45","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jointm.2022.01.004","volume":"2","author":"M Lescroart","year":"2022","unstructured":"Lescroart M, Pequignot B, Kimmoun A, Klein T, Levy B (2022) Beta-blockers in septic shock: what is new? J Intensive Med 2(3):150\u2013155. https:\/\/doi.org\/10.1016\/j.jointm.2022.01.004","journal-title":"J Intensive Med"},{"issue":"suppl_A","key":"396_CR46","doi-asserted-by":"publisher","first-page":"A10","DOI":"10.1093\/eurheartj\/sux036","volume":"20","author":"M Balik","year":"2018","unstructured":"Balik M, Sander M, Trimmel H, Heinz G (2018) Landiolol for managing post-operative atrial fibrillation. Eur Heart J Suppl 20(suppl_A):A10\u2013A14. https:\/\/doi.org\/10.1093\/eurheartj\/sux036","journal-title":"Eur Heart J Suppl"},{"key":"396_CR47","unstructured":"Li L, Ai Q, Lin L, Ge P, Yang C, Zhang L. Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(7):10265\u201373. PubMed PMID: 26379818; PubMed Central PMCID: PMC4565201."},{"issue":"4","key":"396_CR48","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12325-014-0116-x","volume":"31","author":"A Sakamoto","year":"2014","unstructured":"Sakamoto A, Hamasaki T, Kitakaze M (2014) Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Adv Ther 31(4):440\u2013450. https:\/\/doi.org\/10.1007\/s12325-014-0116-x","journal-title":"Adv Ther"},{"issue":"4","key":"396_CR49","first-page":"91","volume":"62","author":"T Kondo","year":"2013","unstructured":"Kondo T, Kusunoki S, Kuroda M, Kawamoto M (2013) Difficult anesthesia management in a case of living donor liver transplantation with hypertrophic obstructive cardiomyopathy. Hiroshima J Med Sci 62(4):91\u20134","journal-title":"Hiroshima J Med Sci"},{"key":"396_CR50","doi-asserted-by":"publisher","DOI":"10.1177\/20503121251413649","volume":"14","author":"L Huang","year":"2026","unstructured":"Huang L, Liu C, Zhang C, Dou Q (2026) Research progress on beta-blockers in the treatment of sepsis-induced cardiomyopathy: a mini review. SAGE Open Med 14:20503121251413649. https:\/\/doi.org\/10.1177\/20503121251413649","journal-title":"SAGE Open Med"},{"issue":"5","key":"396_CR51","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/cc8026","volume":"13","author":"E De Montmollin","year":"2009","unstructured":"De Montmollin E, Aboab J, Mansart A, Annane D (2009) Bench-to-bedside review: \u03b2-adrenergic modulation in sepsis. Crit Care 13(5):230. https:\/\/doi.org\/10.1186\/cc8026","journal-title":"Crit Care"},{"issue":"4","key":"396_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16040517","volume":"16","author":"M Floria","year":"2024","unstructured":"Floria M, Oancea AF, Morariu PC, Burlacu A, Iov DE, Chiriac CP et al (2024) An overview of the pharmacokinetics and pharmacodynamics of landiolol (an ultra-short acting \u03b21 selective antagonist) in atrial fibrillation. Pharmaceutics 16(4):517. https:\/\/doi.org\/10.3390\/pharmaceutics16040517","journal-title":"Pharmaceutics"},{"issue":"2","key":"396_CR53","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.joa.2015.09.002","volume":"32","author":"Y Wada","year":"2016","unstructured":"Wada Y, Aiba T, Tsujita Y, Itoh H, Wada M, Nakajima I et al (2016) Practical applicability of landiolol, an ultra\u2010short\u2010acting \u03b21\u2010selective blocker, for rapid atrial and ventricular tachyarrhythmias with left ventricular dysfunction. J Arrhythm 32(2):82\u20138. https:\/\/doi.org\/10.1016\/j.joa.2015.09.002","journal-title":"J Arrhythm"},{"issue":"6","key":"396_CR54","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.jtcvs.2010.10.045","volume":"141","author":"A Sezai","year":"2011","unstructured":"Sezai A, Minami K, Nakai T, Hata M, Yoshitake I, Wakui S et al (2011) Landiolol hydrochloride for prevention of atrial fibrillation after coronary artery bypass grafting: New evidence from the PASCAL trial. J Thorac Cardiovasc Surg 141(6):1478\u201387. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.10.045","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"15","key":"396_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25158058","volume":"25","author":"AM Eraky","year":"2024","unstructured":"Eraky AM, Yerramalla Y, Khan A, Mokhtar Y, Alamrosy M, Farag A et al (2024) Beta-blockers as an immunologic and autonomic manipulator in critically ill patients: A review of the recent literature. Int J Mol Sci 25(15):8058. https:\/\/doi.org\/10.3390\/ijms25158058","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-026-00396-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-026-00396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-026-00396-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:39:51Z","timestamp":1782776391000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s44158-026-00396-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s44158-026-00396-6","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FA served as an advisor for AOP Pharma, which is developing products related to the research reported in this article. CB, FF and SS received speaker honoraria from AOP Pharma for a clinical case presentation. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"88"}}